On January 26, 2026 (after trading hours), HANSOH PHARMA (03692) announced that the company entered into a subscription agreement with the placing agents. Under the terms of the subscription agreement, the company has conditionally agreed to issue, and the placing agents have conditionally agreed to subscribe and pay for the bonds on a several but not joint basis, subject to certain conditions stipulated in the agreement. The bonds are convertible into new shares in accordance with their specific terms and conditions.

Assuming the bonds are fully converted at an initial conversion price of HK$57.39 per share, and assuming no further issuance of shares by the company, the bonds would be convertible into 81.5473 million shares (with a total nominal value of approximately HK$815). This represents about 1.35% of the company's issued share capital as of the announcement date and approximately 1.33% of the enlarged issued share capital following the full conversion of the bonds.

The new shares to be issued upon conversion of the bonds will, in all respects, rank equally with the existing shares in issue on the relevant record date, enjoying identical rights and privileges. After deducting commissions and other related expenses, the net proceeds from the bond issuance are expected to be approximately HK$4.64 billion. Based on the initial conversion price, the net issue price per converted share is approximately HK$56.90.

The company will apply to the Vienna Stock Exchange for the approval of the listing and trading of the bonds on its Vienna MTF market. The company will also apply to The Stock Exchange of Hong Kong Limited for the listing and trading of the conversion shares.